

Over-The-Counter Ophthalmic Drops: An Eye-Opening Cause of Eyelid Dermatitis

Authors: *Yash Jani,¹ Kaitlyn J. Blanchard,² Cody C. Blanchard,³ Kathryn Anne Potter²

1. Medical College of Georgia, Augusta, USA
 2. Department of Dermatology, Medical College of Georgia, Augusta, USA
 3. Department of Ophthalmology, University of Kentucky College of Medicine, Lexington, USA
- *Correspondence to yjani@augusta.edu

Disclosure: The authors have declared no conflicts of interest.

Keywords: Allergic contact dermatitis, benzalkonium chloride, blepharoconjunctivitis, eyelid dermatitis, ophthalmic drops, patch testing, periocular dermatitis, preservatives.

Citation: *Dermatol AMJ.* 2026;3[1]:52-54.
<https://doi.org/10.33590/dermatolamj/OM062L8W>

BACKGROUND AND AIMS

Eyelid dermatitis represents a unique diagnostic challenge due to the thin periocular skin, increased permeability, and frequent exposure to topical agents, which amplify inflammatory responses even at low levels of exposure.^{1,2} While cosmetics are well-recognized triggers, over-the-counter (OTC) ophthalmic drops remain an underrecognized cause of both allergic and irritant contact dermatitis, often resulting in delayed diagnosis and inappropriate management.¹⁻³

This review characterizes the epidemiology, causative agents, pathophysiology, diagnostic challenges, and management implications of eyelid contact dermatitis associated with OTC ophthalmic drops.

MATERIALS AND METHODS

A focused literature review was conducted using PubMed and Embase, emphasizing preservative systems, active pharmaceutical ingredients, and diagnostic strategies

including standard patch testing and patient product ('as is') testing.¹

Allergic contact dermatitis from OTC ophthalmic drops is primarily a Type IV delayed hypersensitivity reaction mediated by T lymphocytes, typically presenting 24–72 hours after exposure.³ Preservatives, such as benzalkonium chloride, play a central role by disrupting epidermal barrier integrity while simultaneously promoting sensitization, leading to overlapping irritant and allergic mechanisms.^{4,5} Common offending agents include preservatives (benzalkonium chloride, thimerosal, parabens), antibiotics (neomycin, bacitracin), and excipients such as propylene glycol, many of which have well-documented sensitization potential (Table 1).¹

Clinically, patients present with pruritic, erythematous, and edematous plaques involving the upper and/or lower eyelids, often with a characteristic 'tear-drip' distribution.⁶ Conjunctival involvement may result in chronic blepharoconjunctivitis. Importantly, patients frequently fail to recognize OTC ophthalmic drops as potential triggers unless specifically questioned, contributing to diagnostic delay.³ Diagnostic pitfalls commonly arise when clinicians focus exclusively on cosmetic exposures or rely solely on standard patch testing, which may fail to identify ophthalmic-specific allergens.^{1,3}

RESULTS

Identification and avoidance of the offending agent remain the cornerstone of management.^{5,7} Preservative-free or single-use ophthalmic formulations are preferred for patients requiring chronic therapy. Acute flares may be treated with low-potency topical corticosteroids, used cautiously in the periocular region. Early dermatologic involvement facilitates targeted allergen

Table 1: Common offending agents in over-the-counter ophthalmic drops associated with eyelid contact dermatitis.^{3,5-7}

Category	Agent	Clinical relevance
Preservatives	Benzalkonium chloride	Present in ~70% of multi-dose OTC drops; irritant and allergenic; patch-test positivity 1.3–3.1% ^{5,6}
Preservatives	Thimerosal	Patch-test positivity ~9.7%; declining use but continued relevance ⁶
Preservatives	Parabens	Less common sensitizers reported in eyelid ACD ⁷
Preservatives	Chlorobutanol	Preservative associated with delayed hypersensitivity reactions ⁶
Preservatives	EDTA	Chelating agent implicated in ophthalmic ACD ⁷
Antibiotics	Neomycin	High clinical relevance; sensitization rates up to 2.6% ⁶
Antibiotics	Tobramycin	Increasingly reported cause of periorbital ACD ⁵
Antibiotics	Gentamicin	Aminoglycoside with potential cross-reactivity ⁵
Antibiotics	Bacitracin	Recognized cause of eyelid ACD
Antihistamines/decongestants	Ketotifen	Delayed hypersensitivity reactions reported ³
Antihistamines/decongestants	Pheniramine	Antihistamine associated with eyelid ACD ³
Antihistamines/decongestants	Phenylephrine	Vasoconstrictor linked to eyelid edema and ACD ³
Antihistamines/decongestants	Naphazoline	Primarily irritant reactions; occasional allergic responses ³
Excipients/other	Propylene glycol	Common excipient and known contact allergen ⁷
Excipients/other	Lanolin derivatives	Sensitization reported, especially in atopic patients ³
Excipients/other	Sodium metabisulfite	Rare but documented cause of eyelid ACD ³
Excipients/other	Packaging materials (e.g., latex droppers)	Rare but reported source of sensitization

ACD: allergic contact dermatitis; EDTA: ethylenediaminetetraacetic acid; OTC: over-the-counter.

identification, improves counseling, and enables interdisciplinary coordination with ophthalmology to prevent recurrent exposure.⁷

Despite increasing recognition, OTC ophthalmic drop-induced eyelid dermatitis remains a diagnostic blind spot. Barriers include low clinical suspicion, overlapping irritant and allergic mechanisms, and

incomplete allergen identification with standard testing approaches. Expanded diagnostic strategies, including ophthalmic-specific patch testing and direct product testing, may improve diagnostic accuracy and patient outcomes.^{6,7}

CONCLUSION

In conclusion, OTC ophthalmic drops are a frequent yet underrecognized cause of eyelid contact dermatitis. Preservatives and topical antibiotics represent the most common culprits, with benzalkonium chloride playing a key role in barrier disruption and sensitization. Early recognition, targeted history-taking, and appropriate testing are essential to reduce morbidity and avoid unnecessary therapeutic escalation.¹

References

1. Jani Y et al. Over-the-counter ophthalmic drops: an eye-opening cause of eyelid dermatitis. Poster 75986. AAD Annual Meeting, March 27-31, 2026.
2. Pegalajar-García et al. [Allergic contact dermatitis to topical ophthalmic drugs: review of frequently used allergens in Spain]. *Actas Dermosifiliogr*. 2024;115(6):T572-T82. (In Spanish).
3. Amin KA, Belsito DV. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. *Contact Dermatitis*. 2006;55(5):280-5.
4. Glass LRD et al. Patch testing for eyelid dermatitis: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2025;132(7):842-7.
5. Goldstein MH et al. Ocular benzalkonium chloride exposure: problems and solutions. *Eye (Lond)*. 2022;36(2):361-8.
6. Özkaya E et al. Tobramycin and antiglaucoma agents as increasing culprits of periorbital allergic contact dermatitis from topical ophthalmic medications: a 24-year study from Turkey. *Contact Dermatitis*. 2023;89(1):37-45.
7. Nečas M, Dastychová E. Periorbital allergic contact dermatitis - the most common allergens in the Czech Republic. *Int J Ophthalmol Clin Res*. 2017:DOI:10.23937/2378-346X/1410074.